Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 12TCr 7.63Cr 6.71Cr 6.34Cr 5.75Cr 11Cr 732.08Cr 11Cr 76Cr 29Cr 373.57Cr 29Cr 28Cr 1.2TCr P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 35TCr 23Cr 20Cr 19Cr 17Cr 32Cr 2.19TCr 32Cr 226.83Cr 88Cr 1.12TCr 86Cr 84Cr 3.59TCr EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
06/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
11/05 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
07/05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
07/03 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
06/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/25/09 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
06/24/06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
13/24/13 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
07/24/07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
11/24/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
1 day-4.64%
1 week-7.69%
Current month-10.56%
1 month-8.28%
3 months-10.00%
6 months-11.66%
Current year-27.09%
1 week 1,360
Extreme 1360
1,590
1 month 1,360
Extreme 1360
1,635
Current year 1,360
Extreme 1360
2,130
1 year 975
Extreme 975
2,300
3 years 480.5
Extreme 480.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 29/04/2025
Corporate Officer/Principal - 29/04/2025
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-4.64%-7.69%+39.81%+187.43% 7.63Cr
+0.11%+1.71%+63.52%+117.61% 1,05600Cr
+0.27%+0.92%+51.33%+73.35% 66TCr
+0.73%+0.68%+20.70%+74.90% 47TCr
-0.77%-3.16%+37.68%+40.79% 34TCr
+0.08%+4.33%+22.67%+29.43% 28TCr
+1.59%+0.35%+14.68%+14.54% 26TCr
+0.85%+6.35%+53.17%+54.39% 23TCr
+0.85%+1.10%+35.78%+101.82% 19TCr
-0.09%-2.76%-28.41%-60.92% 17TCr
Average -0.19%+0.02%+31.09%+63.33% 36.43TCr
Weighted average by Cap. +0.07%+1.04%+40.45%+69.88%

Financials

2024 2025
Net sales 9.18TCr 6.02Cr 5.3Cr 5.01Cr 4.54Cr 8.53Cr 577.91Cr 8.58Cr 60Cr 23Cr 294.9Cr 23Cr 22Cr 947.64Cr 13TCr 8.31Cr 7.31Cr 6.91Cr 6.27Cr 12Cr 797.84Cr 12Cr 83Cr 32Cr 407.12Cr 31Cr 31Cr 1.31TCr
Net income 2.38TCr 1.56Cr 1.38Cr 1.3Cr 1.18Cr 2.22Cr 150.12Cr 2.23Cr 16Cr 6.01Cr 77Cr 5.87Cr 5.74Cr 246.17Cr 308.78Cr 20.25L 17.81L 16.84L 15.28L 28.69L 19Cr 28.86L 2.02Cr 77.89L 9.92Cr 76.03L 74.39L 32Cr
Net Debt 13TCr 8.77Cr 7.71Cr 7.29Cr 6.61Cr 12Cr 841.41Cr 12Cr 87Cr 34Cr 429.35Cr 33Cr 32Cr 1.38TCr 23TCr 15Cr 13Cr 13Cr 11Cr 21Cr 1.45TCr 22Cr 150.89Cr 58Cr 742.22Cr 57Cr 56Cr 2.39TCr
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
28/26/28 ARS 1,440.00 -4.64% 5,318
25/26/25 ARS 1,510.00 0.00% 2,196
24/26/24 ARS 1,510.00 -0.66% 10,447
23/26/23 ARS 1,520.00 -3.49% 7,769
22/26/22 ARS 1,575.00 +0.96% 349
  1. Stock Market
  2. Stocks
  3. RICH Stock